Cited by 59

MicroRNAs as therapeutic targets and their potential applications in cancer therapy

Cho, William CS·2012·Expert Opinion on Therapeutic Targets

Abstract

Introduction The results of cancer-associated miRNA research have yielded surprising insights into the pathogenesis of a range of different cancers. Many of the dysregulated miRNAs are involved in the regulation of genes that are essential for carcinogenesis. Areas covered This review discusses the latest discovery of miRNAs acting as oncogenes and tumor suppressor genes, as well as the potential applications of miRNA regulations in cancer therapy. Several translational studies have demonstrated the feasibility of targeting oncogenic miRNAs and restoring tumor-suppressive miRNAs for cancer therapy using in vivo model systems. Expert opinion miRNAs are extensive regulators of cancer progression. With increasing understanding of the miRNA target genes and the cellular behaviors influenced by them, modulating the miRNA activities may provide exciting opportunities for cancer therapy. Despite the hurdles incurred in acquiring effective systemic drug delivery systems, in vivo delivery of miRNAs for therapeutic purposes in preclinical animal models is rapidly developing. Accumulating evidences indicate that using miRNA expression alterations to influence molecular pathways has the potential of being translated into clinical applications.

Integrity signals

Registry

Crossref · 10.1517/14728222.2012.696102

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miRNA-based therapeutics have an advantage over antibody therapy such as anti-Lingo1 because miRNAs are more stable.

    “miRNA-based therapeutics have an advantage over antibody therapy such as anti-Lingo1 as miRNAs are more stable (Cho, 2012; Vicente et al., 2016).”

Cited by

Sorted by citations

Authors
Cho, W. C.
Venue
Expert Opinion on Therapeutic Targets
Published
2012-06-13
Volume
16
Issue
8
Pages
747-759
ISSN
  • 1472-8222
  • 1744-7631
Cited by
59
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review